These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17463029)

  • 21. A multivariate analysis approach to the integration of proteomic and gene expression data.
    Fagan A; Culhane AC; Higgins DG
    Proteomics; 2007 Jun; 7(13):2162-71. PubMed ID: 17549791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and evaluation of Actichip, a thematic microarray for the study of the actin cytoskeleton.
    Muller J; Mehlen A; Vetter G; Yatskou M; Muller A; Chalmel F; Poch O; Friederich E; Vallar L
    BMC Genomics; 2007 Aug; 8():294. PubMed ID: 17727702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. R/parallel--speeding up bioinformatics analysis with R.
    Vera G; Jansen RC; Suppi RL
    BMC Bioinformatics; 2008 Sep; 9():390. PubMed ID: 18808714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimized detection of differential expression in global profiling experiments: case studies in clinical transcriptomic and quantitative proteomic datasets.
    Elo LL; Hiissa J; Tuimala J; Kallio A; Korpelainen E; Aittokallio T
    Brief Bioinform; 2009 Sep; 10(5):547-55. PubMed ID: 19549804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An error model for protein quantification.
    Kreutz C; Bartolome Rodriguez MM; Maiwald T; Seidl M; Blum HE; Mohr L; Timmer J
    Bioinformatics; 2007 Oct; 23(20):2747-53. PubMed ID: 17768165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect size, confidence interval and statistical significance: a practical guide for biologists.
    Nakagawa S; Cuthill IC
    Biol Rev Camb Philos Soc; 2007 Nov; 82(4):591-605. PubMed ID: 17944619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptidomics: the integrated approach of MS, hyphenated techniques and bioinformatics for neuropeptide analysis.
    Boonen K; Landuyt B; Baggerman G; Husson SJ; Huybrechts J; Schoofs L
    J Sep Sci; 2008 Feb; 31(3):427-45. PubMed ID: 18266258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probing cellular complexity with proteomics.
    Blackstock W; Rowley A
    Curr Opin Mol Ther; 1999 Dec; 1(6):702-11. PubMed ID: 19629867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass spectrometry is only one piece of the puzzle in clinical proteomics.
    McGuire JN; Overgaard J; Pociot F
    Brief Funct Genomic Proteomic; 2008 Jan; 7(1):74-83. PubMed ID: 18308835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of differentially expressed gene categories in microarray studies using nonparametric multivariate analysis.
    Nettleton D; Recknor J; Reecy JM
    Bioinformatics; 2008 Jan; 24(2):192-201. PubMed ID: 18042553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comments on 'On correcting the overestimation of the permutation-based false discovery rate estimator'.
    Xie Y
    Bioinformatics; 2008 Oct; 24(20):2420. PubMed ID: 18762484
    [No Abstract]   [Full Text] [Related]  

  • 34. Two-stage designs for phase II cancer trials with ordinal responses.
    Stallard N; Cockey L
    Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium.
    Niu HT; Zhang YB; Jiang HP; Cheng B; Sun G; Wang Y; E YJ; Pang de Q; Chang JW
    Urol Oncol; 2009; 27(4):400-6. PubMed ID: 18818109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic feature maps: a new visualization approach in proteomics analysis.
    Giannopoulou EG; Garbis SD; Vlahou A; Kossida S; Lepouras G; Manolakos ES
    J Biomed Inform; 2009 Aug; 42(4):644-53. PubMed ID: 19535004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The proteios software environment: an extensible multiuser platform for management and analysis of proteomics data.
    Häkkinen J; Vincic G; Månsson O; Wårell K; Levander F
    J Proteome Res; 2009 Jun; 8(6):3037-43. PubMed ID: 19354269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global quantitative proteomic profiling through 18O-labeling in combination with MS/MS spectra analysis.
    White CA; Oey N; Emili A
    J Proteome Res; 2009 Jul; 8(7):3653-65. PubMed ID: 19400582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.